MiRNAs and LincRNAs: Could They Be Considered as Biomarkers in Colorectal Cancer?

Por Zarate, Ruth, Boni, Valentina, Bandres, Eva, Garcia-Foncillas, Jesús
Publicado em 2012

Increased vulnerability of clinical research units during the COVID‐19 crisis and their protection

Por de Miguel, Maria, Doger, Bernard, Boni, Valentina, Hernández‐Guerrero, Tatiana, Moreno, Irene, Morillo, Daniel, Moreno, Victor, Calvo, Emiliano
Publicado no Cancer (2020)

Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array

Por Abajo, Ana, Bitarte, Nerea, Zarate, Ruth, Boni, Valentina, Lopez, Ines, Gonzalez-Huarriz, Marisol, Rodriguez, Javier, Bandres, Eva, Garcia-Foncillas, Jesus
Publicado em 2012

Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection

Por Garcia-Carbonero, Rocio, Salazar, Ramon, Duran, Ignacio, Osman-Garcia, Ignacio, Paz-Ares, Luis, Bozada, Juan M., Boni, Valentina, Blanc, Christine, Seymour, Len, Beadle, John, Alvis, Simon, Champion, Brian, Calvo, Emiliano, Fisher, Kerry
Publicado no J Immunother Cancer (2017)

Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis

Por Fudio, Salvador, Tabernero, Josep, Subbiah, Vivek, Chawla, Sant P., Moreno, Victor, Longo, Federico, Lopez, Rafael, Anton, Antonio, Trigo, Jose Manuel, Shapiro, Geoffrey, Jeong, Woondong, Villalobos, Victor Manuel, Lubomirov, Rubin, Fernandez-Teruel, Carlos, Alfaro, Vicente, Boni, Valentina
Publicado no Cancer Chemother Pharmacol (2020)

EPCT-08. ACTIVITY OF LAROTRECTINIB IN PEDIATRIC TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS

Por Goto, Hiroaki, Geoerger, Birgit, DuBois, Steven G, Grilley-Olson, Juneko E, van Tilburg, Cornelis M, Schulte, Johannes, Kang, Hyoung Jin, Tahara, Makoto, Boni, Valentina, Perreault, Sebastien, Capra, Michael, Reeves, John A, Brega, Nicoletta, Childs, Barrett H, Laetsch, Theodore W, Ziegler, David S, Doz, François
Publicado no Neuro Oncol (2020)

RARE-45. ACTIVITY OF LAROTRECTINIB IN TRK FUSION CANCER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM TUMORS

Por Doz, Francois, Geoerger, Birgit, DuBois, Steven G, Grilley-Olson, Juneko E, van Tilburg, Cornelis M, Italiano, Antoine, Lissat, Andrej, Jin Kang, Hyoung, Tahara, Makoto, Boni, Valentina, Perreault, Sebastien, Capra, Michael, Nanda, Shivani, Brega, Nicoletta, Holynskyj, Ariadna, Ziegler, David S, Hong, David S, Hyman, David M, Drilon, Alexander
Publicado no Neuro Oncol (2019)

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial

Por Naumann, R. Wendel, Hollebecque, Antoine, Meyer, Tim, Devlin, Michael-John, Oaknin, Ana, Kerger, Joseph, López-Picazo, Jose M., Machiels, Jean-Pascal, Delord, Jean-Pierre, Evans, Thomas R.J., Boni, Valentina, Calvo, Emiliano, Topalian, Suzanne L., Chen, Tian, Soumaoro, Ibrahima, Li, Bin, Gu, Junchen, Zwirtes, Ricardo, Moore, Kathleen N.
Publicado no J Clin Oncol (2019)

CTNI-67. EFFICACY AND SAFETY OF LAROTRECTINIB IN PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS: AN EXPANDED DATASET

Por Perreault, Sébastien, Doz, François, Drilon, Alexander, Geoerger, Birgit, Boni, Valentina, Chisholm, Julia, Dubois, Steven G, Grilley-Olson, Juneko E, Hong, David S, Italiano, Antoine, Kang, HyoungJin, Nysom, Karsten, Øra, Ingrid, Owens, Cormac, Schulte, Johannes H, Tahara, Makoto, Ziegler, David, Ellezam, Benjamin, Reeves, John A, Fellous, Marc, De La Cuesta, Esther, Laetsch, Theodore W, van Tilburg, Cornelis M
Publicado no Neuro Oncol (2020)

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

Por Cocco, Emiliano, Carmona, F. Javier, Razavi, Pedram, Won, Helen H., Cai, Yanyan, Rossi, Valentina, Chan, Carmen, Cownie, James, Soong, Joanne, Toska, Eneda, Shifman, Sophie G, Sarotto, Ivana, Savas, Peter, Wick, Michael J., Papadopoulos, Kyriakos P., Moriarty, Alyssa, Cutler, Richard E., Avogadri-Connors, Francesca, Lalani, Alshad S., Bryce, Richard P., Chandarlapaty, Sarat, Hyman, David M., Solit, David B., Boni, Valentina, Loi, Sherene, Baselga, José, Berger, Michael F., Montemurro, Filippo, Scaltriti, Maurizio
Publicado no Sci Signal (2018)

Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib

Por Cebrián, Arancha, Gómez del Pulgar, Teresa, Méndez-Vidal, María José, Gonzálvez, María Luisa, Lainez, Nuria, Castellano, Daniel, García-Carbonero, Iciar, Esteban, Emilio, Sáez, Maria Isabel, Villatoro, Rosa, Suárez, Cristina, Carrato, Alfredo, Munárriz-Ferrándiz, Javier, Basterrechea, Laura, García-Alonso, Mirta, González-Larriba, José Luis, Perez-Valderrama, Begoña, Cruz-Jurado, Josefina, González del Alba, Aránzazu, Moreno, Fernando, Reynés, Gaspar, Rodríguez-Remírez, María, Boni, Valentina, Mahillo-Fernández, Ignacio, Martin, Yolanda, Viqueira, Andrea, García-Foncillas, Jesús
Publicado no Sci Rep (2017)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Por Hyman, David M., Piha-Paul, Sarina A., Won, Helen, Rodon, Jordi, Saura, Cristina, Shapiro, Geoffrey I., Juric, Dejan, Quinn, David I., Moreno, Victor, Doger, Bernard, Mayer, Ingrid A., Boni, Valentina, Calvo, Emiliano, Loi, Sherene, Lockhart, Albert C., Erinjeri, Joseph P., Scaltriti, Maurizio, Ulaner, Gary A., Patel, Juber, Tang, Jiabin, Beer, Hannah, Selcuklu, S. Duygu, Hanrahan, Aphrothiti J., Bouvier, Nancy, Melcer, Myra, Murali, Rajmohan, Schram, Alison M., Smyth, Lillian M., Jhaveri, Komal, Li, Bob T., Drilon, Alexander, Harding, James J., Iyer, Gopa, Taylor, Barry S., Berger, Michael F., Cutler, Richard E., Xu, Feng, Butturini, Anna, Eli, Lisa D., Mann, Grace, Farrell, Cynthia, Lalani, Alshad S., Bryce, Richard P., Arteaga, Carlos L., Meric-Bernstam, Funda, Baselga, José, Solit, David B.
Publicado no Nature (2018)

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

Por Smyth, Lillian M., Piha-Paul, Sarina A., Won, Helen, Schram, Alison M., Saura, Cristina, Loi, Sherene, Lu, Janice, Shapiro, Geoffrey I., Juric, Dejan, Mayer, Ingrid A., Arteaga, Carlos L., de la Fuente, Macarena I., Brufksy, Adam M., Spanggaard, Iben, Mau-Sørensen, Morten, Arnedos, Monica, Moreno, Victor, Boni, Valentina, Sohn, Joohyuk, Schwartzberg, Lee S., Gonzàlez-Farré, Xavier, Cervantes, Andrés, Bidard, François-Clement, Gorelick, Alexander N., Lanman, Richard B., Nagy, Rebecca J., Ulaner, Gary A., Chandarlapaty, Sarat, Jhaveri, Komal, Gavrila, Elena I., Zimel, Catherine, Selcuklu, S. Duygu, Melcer, Myra, Samoila, Aliaksandra, Cai, Yanyan, Scaltriti, Maurizio, Mann, Grace, Xu, Feng, Eli, Lisa D., Dujka, Melanie, Lalani, Alshad S., Bryce, Richard, Baselga, José, Taylor, Barry S., Solit, David B., Meric-Bernstam, Funda, Hyman, David M.
Publicado no Cancer Discov (2019)